Developer docs
API playgroundTry for free, no card

Search company profiles

e-NIOS

Full company profile

uuid0006l94

Namestring
e-NIOS
Legal namestring
ENIOS APPLICATIONS PC
Websiteurl
e-nios.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

e-NIOS (legal entity ENIOS APPLICATIONS PC) is a Greek bioinformatics company that develops BioInfoMiner, an AI-powered multi-omic interpretation platform designed to translate high-throughput molecular data into mechanistically explainable biological insights. Founded in 2014 and headquartered in Kallithea, Athens, the company targets the interpretation bottleneck pharmaceutical and biotechnology companies face when moving from raw omic data to actionable drug targets, with secondary reach into academic and precision medicine research. The company is small, with 1-10 employees per firmographic data.

The BioInfoMiner platform applies a proprietary semantic processing algorithm to transform raw biological annotation terms from curated ontologies (Gene Ontology, Human Phenotype Ontology, Mammalian Phenotype Ontology, REACTOME pathways) into noise-free knowledge networks. Graph-theoretic prioritization then identifies structurally central biological processes, correcting for annotation bias where heavily studied genes dominate results, and ranks driver or linker genes between prioritized processes to produce compact molecular signatures. The platform unifies interpretation across transcriptomics, genomics, epigenomics, and proteomics in a single auditable pipeline, and has been validated in 50+ peer-reviewed publications in journals including Nature Communications, Cell Metabolism, EMBO Molecular Medicine, J Cell Biol, Bioinformatics, and Scientific Reports.

e-NIOS operates a hybrid revenue model with three streams: BioInfoMiner platform licensing (subscription-style recurring access on a quote-based, undisclosed price structure), collaborative research partnerships delivered as professional services, and public research grants from European and national programmes including Horizon Europe, EPAnEK, Marie Skłodowska-Curie actions, and Erasmus+. Distribution runs through direct enterprise sales to pharmaceutical and biotech firms, plus an OEM channel via a 2018 strategic integration with the Seven Bridges biomedical data platform. Pricing is not publicly disclosed; the company's website explicitly invites licensing inquiries and research collaborations.

Short descriptiontext

e-NIOS is a Greek bioinformatics company developing BioInfoMiner, an AI-powered multi-omic interpretation platform that grounds AI models to biological mechanisms for pharmaceutical researchers, biotech firms, and precision medicine applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersKallithéa, Greece
HQ citystring
Kallithéa
HQ countrystring
Greece
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
multi-omic interpretation, bioinformatics platform, AI drug discovery, biomarker identification, precision medicine analytics
Industry3 codes
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Bioinformatics Software
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1BioInfoMiner Platform Licensing
TypeSubscription Recurring
Description

License-based access to the BioInfoMiner platform for multi-omic data interpretation. The company mentions being open for licensing inquiries.

e-nios.com
2Research Partnerships
TypeProfessional Services
Description

Collaborative research partnerships with academic institutions and pharmaceutical companies, contributing bioinformatics analysis services using the BioInfoMiner platform.

e-nios.com
3Public Research Grants
TypeLicensing Royalties
Description

Funding from European and national research programmes including Horizon Europe, EPAnEK, Marie Skłodowska-Curie actions, and Erasmus+ initiatives.

e-nios.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1BioInfoMiner
Description

Advanced interpretation engine that grounds AI models to mechanistic biology through sophisticated semantic processing, enabling rapid detection of causal genes and biological mechanisms with full transparency.

e-nios.com
Core offering1 text field

e-NIOS provides BioInfoMiner, a software platform that performs unsupervised, explainable AI-assisted interpretation of multi-omic data (transcriptomics, genomics, epigenomics, proteomics). The platform grounds AI predictions to biological mechanisms through semantic network construction, delivering prioritized biomarker signatures, driver gene identification, and pathway analysis to pharmaceutical, biotech, and academic research customers via licensing and collaborative research partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Over 90% of drug candidates fail in clinical trials, with significant failures attributed to flawed target selection from pre-clinical omic data interpretation - e-NIOS addresses this critical bottleneck
Product overview1 text field

e-NIOS offers a single unified platform called BioInfoMiner, which is a next-generation omic interpretation engine that performs automated, explainable AI-assisted multi-omic analysis. The platform integrates diverse omics data (transcriptomics, genomics, epigenomics, proteomics) through advanced semantic processing, delivering actionable biological insights from raw omic data to prioritized signatures and driver genes.

Product and service2 records
1BioInfoMiner Platform
CategoryBioinformatics Software
Description

AI-powered multi-omic interpretation platform that performs unsupervised, explainable analysis of transcriptomics, genomics, epigenomics, and proteomics data. Grounds AI models to biological mechanisms through advanced semantic processing, delivering prioritized biomarker signatures, driver gene identification, and pathway analysis for pharmaceutical, biotech, and academic research customers.

2Multi-Omic Interpretation Services
CategoryResearch Collaboration Services
Description

Collaborative bioinformatics analysis services delivered through research partnerships with academic institutions and pharmaceutical companies, applying BioInfoMiner to interpret customer-supplied multi-omic datasets, identify mechanisms of action, and produce molecular biomarkers (e.g., TheraSyn RNAseq analysis for Parkinson's disease antisense therapy).

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-09-11
Description

Strategic partnership announced in September 2018 to break the biomarker bottleneck. BioInfoMiner was integrated into the Seven Bridges biomedical data platform for data-driven discovery of biomarker signatures. This integration enabled Seven Bridges users to access e-NIOS's advanced multi-omic interpretation capabilities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

MSCA-SE project funded by the European Commission focused on understanding how tumours evade the immune system. e-NIOS contributes advanced in silico modelling tools based on AI and Machine Learning to modulate non-canonical death receptor signalling, making tumours sensitive to cell death again.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Marie Skłodowska-Curie and Horizon 2020 project bringing together researchers in cell death signalling, immunology, protein structural chemistry, drug design, bioinformatics and computational biology. e-NIOS contributes bioinformatics expertise to this cross-sectoral network.

4INSPIRED Network (IRE1 Biology & Drug Discovery)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Network of academic and industry researchers in IRE1 biology and drug discovery. e-NIOS shares knowledge and expertise to develop new treatments for cancer and neurodegenerative diseases.

e-nios.com
5TRAIN-ERS Network (Endoplasmic Reticulum Stress Research)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Endoplasmic Reticulum stress research network bringing researchers together with world-leading academics, clinicians and industry personnel. e-NIOS participates in advancing understanding of ER Stress Response and innovative treatment strategies.

e-nios.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

International research and innovation network where e-NIOS participates as a computational biology and bioinformatics partner, contributing expertise in multi-omic data interpretation to support network-wide research objectives including breast cancer nano-pharmaceuticals development.

7BioS Project (Erasmus+ / Sector Skills Alliances)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Erasmus+ Sector Skills Alliance project 'Digital Skills on Computational Biology' aimed at advancing digital skills of medical doctors through new modular vocational curricula on Computational Biology & Bioinformatics.

e-nios.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Nationally funded collaborative research project developing next generation anti-sense molecules for Parkinson's disease therapy. e-NIOS performed comprehensive bioinformatics analysis of RNAseq data using BioInfoMiner, helping assess mechanisms of action and identify molecular biomarkers.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

EU co-funded project (EPAnEK 2014-2020) applying metagenomics and bioinformatics technologies for identification of microorganisms affecting stone surfaces of monuments and development of nano-biomaterials for cultural heritage protection.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Biomedical data analysis platform serving pharma and research institutions. e-NIOS already has a strategic partnership with Seven Bridges integrating BioInfoMiner, making them both a distribution channel and a potential competitive platform if Seven Bridges builds native interpretation capabilities.

TypeDirect peer
Description

Cloud-based genomics and biomedical data platform serving pharma R&D and clinical diagnostics. Competes directly for enterprise pharma bioinformatics budgets and offers integrated multi-omic analysis capabilities similar to BioInfoMiner's positioning.

TypeDirect peer
Description

Enterprise bioinformatics software for pharma R&D, with established penetration in top-20 pharma. Provides similar multi-omic data interpretation capabilities and competes for the same pharmaceutical enterprise licensing budgets as BioInfoMiner.

TypeDirect peer
Description

AI-powered genomics platform for clinical and research applications, with public-company scale and global footprint. Competes in the same AI-driven multi-omic interpretation category targeting hospitals and pharma.

TypeDirect peer
Description

Cloud-based bioinformatics platform for multi-omic data analysis with emphasis on biologist-friendly interpretation. Targets similar pharma and academic customers and offers competing explainable analysis capabilities.

TypeDirect peer
Description

Bioinformatics software suite for genomic and multi-omic data analysis, now backed by Illumina's sequencing market dominance. Offers similar transcriptomics and genomics interpretation workflows to BioInfoMiner with broader commercial reach.

TypeBroad incumbent
Description

Dominant sequencing and genomics platform with expanding bioinformatics portfolio including Partek and DRAGEN. Represents a broad incumbent that could bundle competing interpretation capabilities with sequencing instruments to squeeze independent platforms like BioInfoMiner.

TypeBroad incumbent
Description

Bioinformatics business unit of Qiagen providing genomic and clinical interpretation software. Serves similar pharma and clinical customers with a broader portfolio that includes sample technologies, competing for the same interpretation spend.

TypeBroad incumbent
Description

Computational chemistry and molecular simulation platform with expanding biology capabilities. Public company with resources to extend into multi-omic interpretation, potentially competing with BioInfoMiner in the target identification and biomarker discovery workflows.

TypeEmerging player
Description

Genomics and real-world data platform focused on precision medicine partnerships with pharma. Smaller-scale emerging player in the same bioinformatics-for-precision-medicine category as e-NIOS, with comparable go-to-market through pharma collaborations.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

e-NIOS

Bioinformatics Softwaree-nios.com

e-NIOS is a Greek bioinformatics company developing BioInfoMiner, an AI-powered multi-omic interpretation platform that grounds AI models to biological mechanisms for pharmaceutical researchers, biotech firms, and precision medicine applications.

What e-NIOS does

e-NIOS (legal entity ENIOS APPLICATIONS PC) is a Greek bioinformatics company that develops BioInfoMiner, an AI-powered multi-omic interpretation platform designed to translate high-throughput molecular data into mechanistically explainable biological insights. Founded in 2014 and headquartered in Kallithea, Athens, the company targets the interpretation bottleneck pharmaceutical and biotechnology companies face when moving from raw omic data to actionable drug targets, with secondary reach into academic and precision medicine research. The company is small, with 1-10 employees per firmographic data.

The BioInfoMiner platform applies a proprietary semantic processing algorithm to transform raw biological annotation terms from curated ontologies (Gene Ontology, Human Phenotype Ontology, Mammalian Phenotype Ontology, REACTOME pathways) into noise-free knowledge networks. Graph-theoretic prioritization then identifies structurally central biological processes, correcting for annotation bias where heavily studied genes dominate results, and ranks driver or linker genes between prioritized processes to produce compact molecular signatures. The platform unifies interpretation across transcriptomics, genomics, epigenomics, and proteomics in a single auditable pipeline, and has been validated in 50+ peer-reviewed publications in journals including Nature Communications, Cell Metabolism, EMBO Molecular Medicine, J Cell Biol, Bioinformatics, and Scientific Reports.

e-NIOS operates a hybrid revenue model with three streams: BioInfoMiner platform licensing (subscription-style recurring access on a quote-based, undisclosed price structure), collaborative research partnerships delivered as professional services, and public research grants from European and national programmes including Horizon Europe, EPAnEK, Marie Skłodowska-Curie actions, and Erasmus+. Distribution runs through direct enterprise sales to pharmaceutical and biotech firms, plus an OEM channel via a 2018 strategic integration with the Seven Bridges biomedical data platform. Pricing is not publicly disclosed; the company's website explicitly invites licensing inquiries and research collaborations.

e-NIOS firmographics

Firmographics
Name
e-NIOS
Legal name
ENIOS APPLICATIONS PC
Website
https://e-nios.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
e-NIOS is a Greek bioinformatics company developing BioInfoMiner, an AI-powered multi-omic interpretation platform that grounds AI models to biological mechanisms for pharmaceutical researchers, biotech firms, and precision medicine applications.
Ownership category
akta.pro rank

e-NIOS industry classification

Industry
Product category
Bioinformatics Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)

Keywords

  • Multi-omic interpretation
  • Bioinformatics platform
  • AI drug discovery
  • Biomarker identification
  • Precision medicine analytics

Where e-NIOS is headquartered

Location

Headquarters

HQ city
Kallithéa
HQ country
Greece
HQ region
Europe

Offices1 record

Markets served

e-NIOS business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. BioInfoMiner Platform Licensing: License-based access to the BioInfoMiner platform for multi-omic data interpretation. The company mentions being open for licensing inquiries.
  2. Research Partnerships: Collaborative research partnerships with academic institutions and pharmaceutical companies, contributing bioinformatics analysis services using the BioInfoMiner platform.
  3. Public Research Grants: Funding from European and national research programmes including Horizon Europe, EPAnEK, Marie Skłodowska-Curie actions, and Erasmus+ initiatives.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

e-NIOS product offering

Product offering

Core offering

e-NIOS provides BioInfoMiner, a software platform that performs unsupervised, explainable AI-assisted interpretation of multi-omic data (transcriptomics, genomics, epigenomics, proteomics). The platform grounds AI predictions to biological mechanisms through semantic network construction, delivering prioritized biomarker signatures, driver gene identification, and pathway analysis to pharmaceutical, biotech, and academic research customers via licensing and collaborative research partnerships.

Product overview

e-NIOS offers a single unified platform called BioInfoMiner, which is a next-generation omic interpretation engine that performs automated, explainable AI-assisted multi-omic analysis. The platform integrates diverse omics data (transcriptomics, genomics, epigenomics, proteomics) through advanced semantic processing, delivering actionable biological insights from raw omic data to prioritized signatures and driver genes.

Differentiator

Problem solved

Functional benefit

Brands

  • BioInfoMiner: Advanced interpretation engine that grounds AI models to mechanistic biology through sophisticated semantic processing, enabling rapid detection of causal genes and biological mechanisms with full transparency.

Products and services

  • BioInfoMiner Platform AI-powered multi-omic interpretation platform that performs unsupervised, explainable analysis of transcriptomics, genomics, epigenomics, and proteomics data. Grounds AI models to biological mechanisms through advanced semantic processing, delivering prioritized biomarker signatures, driver gene identification, and pathway analysis for pharmaceutical, biotech, and academic research customers.
  • Multi-Omic Interpretation Services Collaborative bioinformatics analysis services delivered through research partnerships with academic institutions and pharmaceutical companies, applying BioInfoMiner to interpret customer-supplied multi-omic datasets, identify mechanisms of action, and produce molecular biomarkers (e.g., TheraSyn RNAseq analysis for Parkinson's disease antisense therapy).

Quantifiable outcome

  • Over 90% of drug candidates fail in clinical trials, with significant failures attributed to flawed target selection from pre-clinical omic data interpretation - e-NIOS addresses this critical bottleneck

Companies that use e-NIOS

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

e-NIOS technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

e-NIOS partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • Seven BridgescoreTechnology or Integration · 11 September 2018Strategic partnership announced in September 2018 to break the biomarker bottleneck. BioInfoMiner was integrated into the Seven Bridges biomedical data platform for data-driven discovery of biomarker signatures. This integration enabled Seven Bridges users to access e-NIOS's advanced multi-omic interpretation capabilities.
  • CHIRON Project (Horizon Europe, Grant No. 101130240)coreStrategic or Co-development PartnerMSCA-SE project funded by the European Commission focused on understanding how tumours evade the immune system. e-NIOS contributes advanced in silico modelling tools based on AI and Machine Learning to modulate non-canonical death receptor signalling, making tumours sensitive to cell death again.
  • DISCOVER Network (Marie Skłodowska-Curie / Horizon 2020)minorStrategic or Co-development PartnerMarie Skłodowska-Curie and Horizon 2020 project bringing together researchers in cell death signalling, immunology, protein structural chemistry, drug design, bioinformatics and computational biology. e-NIOS contributes bioinformatics expertise to this cross-sectoral network.
  • INSPIRED Network (IRE1 Biology & Drug Discovery)minorStrategic or Co-development PartnerNetwork of academic and industry researchers in IRE1 biology and drug discovery. e-NIOS shares knowledge and expertise to develop new treatments for cancer and neurodegenerative diseases.
  • TRAIN-ERS Network (Endoplasmic Reticulum Stress Research)minorStrategic or Co-development PartnerEndoplasmic Reticulum stress research network bringing researchers together with world-leading academics, clinicians and industry personnel. e-NIOS participates in advancing understanding of ER Stress Response and innovative treatment strategies.
  • INNOCENT NetworkminorStrategic or Co-development PartnerInternational research and innovation network where e-NIOS participates as a computational biology and bioinformatics partner, contributing expertise in multi-omic data interpretation to support network-wide research objectives including breast cancer nano-pharmaceuticals development.
  • BioS Project (Erasmus+ / Sector Skills Alliances)minorStrategic or Co-development PartnerErasmus+ Sector Skills Alliance project 'Digital Skills on Computational Biology' aimed at advancing digital skills of medical doctors through new modular vocational curricula on Computational Biology & Bioinformatics.
  • TheraSyn Project (T2EDK-01291)coreStrategic or Co-development PartnerNationally funded collaborative research project developing next generation anti-sense molecules for Parkinson's disease therapy. e-NIOS performed comprehensive bioinformatics analysis of RNAseq data using BioInfoMiner, helping assess mechanisms of action and identify molecular biomarkers.
  • BIOFOS Project (T2EDK-03126)minorStrategic or Co-development PartnerEU co-funded project (EPAnEK 2014-2020) applying metagenomics and bioinformatics technologies for identification of microorganisms affecting stone surfaces of monuments and development of nano-biomaterials for cultural heritage protection.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

e-NIOS competitors and assessment

Company assessment

Direct peers

  • Seven Bridges (Velsera): Biomedical data analysis platform serving pharma and research institutions. e-NIOS already has a strategic partnership with Seven Bridges integrating BioInfoMiner, making them both a distribution channel and a potential competitive platform if Seven Bridges builds native interpretation capabilities.
  • DNAnexus: Cloud-based genomics and biomedical data platform serving pharma R&D and clinical diagnostics. Competes directly for enterprise pharma bioinformatics budgets and offers integrated multi-omic analysis capabilities similar to BioInfoMiner's positioning.
  • Genedata: Enterprise bioinformatics software for pharma R&D, with established penetration in top-20 pharma. Provides similar multi-omic data interpretation capabilities and competes for the same pharmaceutical enterprise licensing budgets as BioInfoMiner.
  • SOPHiA Genetics: AI-powered genomics platform for clinical and research applications, with public-company scale and global footprint. Competes in the same AI-driven multi-omic interpretation category targeting hospitals and pharma.
  • Rosalind (formerly OnRamp Bioinformatics): Cloud-based bioinformatics platform for multi-omic data analysis with emphasis on biologist-friendly interpretation. Targets similar pharma and academic customers and offers competing explainable analysis capabilities.
  • Partek (now part of Illumina): Bioinformatics software suite for genomic and multi-omic data analysis, now backed by Illumina's sequencing market dominance. Offers similar transcriptomics and genomics interpretation workflows to BioInfoMiner with broader commercial reach.

Broad incumbents

  • Illumina: Dominant sequencing and genomics platform with expanding bioinformatics portfolio including Partek and DRAGEN. Represents a broad incumbent that could bundle competing interpretation capabilities with sequencing instruments to squeeze independent platforms like BioInfoMiner.
  • Qiagen Digital Insights: Bioinformatics business unit of Qiagen providing genomic and clinical interpretation software. Serves similar pharma and clinical customers with a broader portfolio that includes sample technologies, competing for the same interpretation spend.
  • Schrödinger: Computational chemistry and molecular simulation platform with expanding biology capabilities. Public company with resources to extend into multi-omic interpretation, potentially competing with BioInfoMiner in the target identification and biomarker discovery workflows.

Emerging players

  • BC Platforms: Genomics and real-world data platform focused on precision medicine partnerships with pharma. Smaller-scale emerging player in the same bioinformatics-for-precision-medicine category as e-NIOS, with comparable go-to-market through pharma collaborations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

e-NIOS social profiles

Digital presence

e-NIOS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

e-NIOS leadership team

Management profile

Number of profiles

Profiles2 records

e-NIOS funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

e-NIOS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about e-NIOS

What does e-NIOS do?

e-NIOS provides BioInfoMiner, a software platform that performs unsupervised, explainable AI-assisted interpretation of multi-omic data (transcriptomics, genomics, epigenomics, proteomics). The platform grounds AI predictions to biological mechanisms through semantic network construction, delivering prioritized biomarker signatures, driver gene identification, and pathway analysis to pharmaceutical, biotech, and academic research customers via licensing and collaborative research partnerships.

Is e-NIOS a public or private company?

e-NIOS is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was e-NIOS founded?

e-NIOS was founded in 2013. It employs 1 to 10 people.

Where is e-NIOS based?

e-NIOS is headquartered in Kallithéa, Greece, in the Europe region.

How does e-NIOS make money?

Three revenue lines are on record. BioInfoMiner Platform Licensing is the primary driver. The others are research Partnerships and public Research Grants.

Who are e-NIOS's main competitors?

Direct peers on record are Seven Bridges (Velsera), DNAnexus, Genedata, SOPHiA Genetics, Rosalind (formerly OnRamp Bioinformatics) and Partek (now part of Illumina). Broad incumbents are Illumina, Qiagen Digital Insights and Schrödinger. BC Platforms is listed as an emerging player.

Does e-NIOS have an API?

No public API is recorded for e-NIOS.

What industry is e-NIOS in?

e-NIOS's product category is Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales